These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10577345)

  • 1. Hepatitis B virus genotypic resistance to lamivudine.
    Fontaine H; Thiers V; Pol S
    Ann Intern Med; 1999 Nov; 131(9):716-7. PubMed ID: 10577345
    [No Abstract]   [Full Text] [Related]  

  • 2. Strategy for lamivudine-resistant YMDD mutant-associated chronic hepatitis B.
    Kiyosawa K; Tanaka E
    J Gastroenterol; 2001 Feb; 36(2):139-41. PubMed ID: 11227673
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico.
    Alvarado-Esquivel C; de la Ascensión Carrera-Gracia M; Conde-González CJ; Juárez-Figueroa L; Ruiz-Maya L; Aguilar-Benavides S; Torres-Valenzuela A; Sablon E
    J Antimicrob Chemother; 2006 Feb; 57(2):221-3. PubMed ID: 16373428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.
    Amini-Bavil-Olyaee S; Hosseini SY; Sabahi F; Alavian SM
    Int J Infect Dis; 2008 Jan; 12(1):83-7. PubMed ID: 17698384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of lamivudine-resistant hepatitis B virus].
    Matsumura M
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():175-9. PubMed ID: 15453310
    [No Abstract]   [Full Text] [Related]  

  • 7. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
    Kim JW; Lee HS; Woo GH; Yoon JH; Jang JJ; Chi JG; Kim CY
    Clin Infect Dis; 2001 Aug; 33(3):403-5. PubMed ID: 11438912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.
    Allen MI; Deslauriers M; Andrews CW; Tipples GA; Walters KA; Tyrrell DL; Brown N; Condreay LD
    Hepatology; 1998 Jun; 27(6):1670-7. PubMed ID: 9620341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.
    Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
    Intervirology; 2003; 46(3):182-9. PubMed ID: 12867757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with lamivudine against hepatitis B virus.
    Jaeckel E; Manns MP
    Intervirology; 1997; 40(5-6):322-36. PubMed ID: 9675637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
    Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.
    Akman SA; Kose S; Halicioglu O
    Int J Infect Dis; 2010 Mar; 14(3):e236-9. PubMed ID: 19665408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy.
    Pai SB; Bozdayi AM; Pai RB; Beker T; Sarioglu M; Turkyilmaz AR; Grier J; Yurdaydin C; Schinazi RF
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2618-24. PubMed ID: 15980328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of the lamivudine-resistant mutants of hepatitis B virus].
    Gervain J; Papp I; Csöndes M; Nemesánszky E; Rácz I; Ribiczey P; Telegdy L; Tornai I; Weisz G
    Orv Hetil; 2003 Jun; 144(25):1251-6. PubMed ID: 12901182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
    Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
    J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan.
    Hayashi K; Katano Y; Takeda Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Nakano I; Yano M; Goto H; Yoshioka K; Toyoda H; Kumada T
    J Med Virol; 2007 Apr; 79(4):366-73. PubMed ID: 17311332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
    Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
    J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.